NO20045369L - Nye, substituerte sulfamatanticonvulsivaderivater - Google Patents

Nye, substituerte sulfamatanticonvulsivaderivater

Info

Publication number
NO20045369L
NO20045369L NO20045369A NO20045369A NO20045369L NO 20045369 L NO20045369 L NO 20045369L NO 20045369 A NO20045369 A NO 20045369A NO 20045369 A NO20045369 A NO 20045369A NO 20045369 L NO20045369 L NO 20045369L
Authority
NO
Norway
Prior art keywords
new
compounds
anticonvulsant derivatives
sulfamate anticonvulsant
substituted
Prior art date
Application number
NO20045369A
Other languages
English (en)
Inventor
Allen B Reitz
Bruce E Maryanoff
Frank J Villani
Cynthia Maryanoff
Ahmed F Abdel-Magid
Cheryl P Kordik
Steven Mehrman
Kirk Sorgi
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20045369L publication Critical patent/NO20045369L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06Aminosugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04Cyclic acetals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

Det beskrives nye forbindelser med formel (I) (I) der X, R\ R^, R', R*, R' og R* er som beskrevet nærmere. Det beskrives nærmere fremgangsmåter for fremstilling av, samt farmasøytiske preparater inneholdende, disse forbindelser. Forbindelsene er bnikbane for behandling av epilepsi. Det beskrives videre en fremgangsmåte for fremstilling av forbindelser med formel (XX) O II O¿S¿NH, II (XX) der X, r', R*, R' og R'^ er som beskrevet nærmere.
NO20045369A 2002-05-13 2004-12-08 Nye, substituerte sulfamatanticonvulsivaderivater NO20045369L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37801702P 2002-05-13 2002-05-13
PCT/US2003/014796 WO2003097656A2 (en) 2002-05-13 2003-05-09 Novel substituted sulfamate anticonvulsant derivatives

Publications (1)

Publication Number Publication Date
NO20045369L true NO20045369L (no) 2004-12-08

Family

ID=29549890

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045369A NO20045369L (no) 2002-05-13 2004-12-08 Nye, substituerte sulfamatanticonvulsivaderivater

Country Status (19)

Country Link
US (2) US7060725B2 (no)
EP (1) EP1506212A2 (no)
JP (1) JP2005526852A (no)
CN (1) CN1665828B (no)
AR (1) AR040412A1 (no)
AU (1) AU2003232112B2 (no)
BR (1) BR0309964A (no)
CA (1) CA2485966A1 (no)
HR (1) HRP20041042A2 (no)
IL (1) IL165108A0 (no)
MX (1) MXPA04011232A (no)
NO (1) NO20045369L (no)
NZ (1) NZ537139A (no)
PL (1) PL373910A1 (no)
RU (1) RU2328502C2 (no)
TW (1) TWI281472B (no)
UA (1) UA78566C2 (no)
WO (1) WO2003097656A2 (no)
ZA (1) ZA200409989B (no)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638291B2 (en) * 2004-10-25 2009-12-29 Seradyn, Inc. Immunoassays for topiramate
US20060088886A1 (en) * 2004-10-25 2006-04-27 Anlong Ouyang Topiramate analogs
WO2007099388A1 (en) * 2006-03-01 2007-09-07 Glade Organics Private Limited An improved process for the manufacture of topiramate
WO2014037832A2 (en) * 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
CA2872975A1 (en) 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
EP2847158A4 (en) 2012-05-07 2015-12-30 Cellix Bio Private Ltd COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS AND NEURODEGENERATIVE DISORDERS
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
JP2015518855A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 粘膜炎の治療のための組成物および方法
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
JP2015518854A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 多発性硬化症の治療のための組成物および方法
JP6202287B2 (ja) 2012-05-23 2017-09-27 セリックスビオ プライヴェート リミテッド 炎症性腸疾患の治療のための組成物及び方法
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
SG11201407325YA (en) 2012-09-08 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of inflammation and lipid disorders
CA2891514C (en) 2012-12-07 2020-08-25 Glycomimetics, Inc. Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
EP3004049B1 (en) 2013-06-04 2018-09-05 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
CN103910770B (zh) * 2014-03-14 2017-01-04 天津南开允公医药科技有限公司 一种托吡酯的制备方法以及该方法中所涉及的中间体晶型及其制备方法
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
EP3201168B1 (en) 2014-09-29 2020-03-18 Cellix Bio Private Limited Compounds and compositions for the treatment of multiple sclerosis
CA2965449C (en) 2014-10-27 2020-11-10 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
EP3242869B1 (en) 2015-01-06 2021-10-27 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and pain
EP3778565A4 (en) * 2018-03-27 2022-03-23 Daikin Industries, Ltd. PROCESS FOR THE PRODUCTION OF LITHIUM SULFAMATE, AND NEW LITHIUM SULFAMATE
CN110655542A (zh) * 2018-06-29 2020-01-07 鲁南制药集团股份有限公司 一种2,3:4,5-双-O-(1-甲基亚乙基)-β-D-吡喃果糖氯磺酸酯的晶型
CN114685526A (zh) * 2020-12-25 2022-07-01 长沙博源医疗科技有限公司 一种托吡酯衍生物、免疫原、抗托吡酯特异性抗体及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
PT94305B (pt) 1989-06-12 1997-02-28 Robins Co Inc A H Processo para a preparacao de compostos tendo um ou mais radicais aminossulfoniloxi uteis como produtos farmaceuticos
US5194446A (en) * 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
US5273993A (en) * 1989-06-12 1993-12-28 A. H. Robins Company, Incorporated Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals
US5192785A (en) * 1989-09-03 1993-03-09 A. H. Robins Company, Incorporated Sulfamates as antiglaucoma agents
US5025031A (en) * 1989-11-30 1991-06-18 A. H. Robins Co., Inc. Aryl and aryloxyalkyl sulfamate esters useful as anticonvulsants
AU651244B2 (en) * 1991-09-19 1994-07-14 Mcneilab, Inc. Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-0-(1-methylethylidene)-beta-D- fructopyranose and (1-methylcyclohexyl)methanol
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
DE69434652T2 (de) 1993-12-23 2007-03-01 Ortho-Mcneil Pharmaceutical, Inc. Antikonvulsive pseudofructopyranose sulfamate
US5998380A (en) 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
US5952187A (en) 1995-12-01 1999-09-14 Oxis International, Inc. Topiramate immunoassay
JP3602906B2 (ja) * 1996-03-05 2004-12-15 富士写真フイルム株式会社 熱現像感光材料

Also Published As

Publication number Publication date
US7060725B2 (en) 2006-06-13
CN1665828B (zh) 2012-06-27
EP1506212A2 (en) 2005-02-16
RU2328502C2 (ru) 2008-07-10
BR0309964A (pt) 2005-03-01
ZA200409989B (en) 2006-02-22
WO2003097656A3 (en) 2004-06-10
US7560459B2 (en) 2009-07-14
US20040038911A1 (en) 2004-02-26
WO2003097656A2 (en) 2003-11-27
RU2004133334A (ru) 2005-06-10
US20060058373A1 (en) 2006-03-16
CA2485966A1 (en) 2003-11-27
CN1665828A (zh) 2005-09-07
TWI281472B (en) 2007-05-21
TW200404078A (en) 2004-03-16
AR040412A1 (es) 2005-04-06
MXPA04011232A (es) 2005-08-16
IL165108A0 (en) 2005-12-18
PL373910A1 (en) 2005-09-19
UA78566C2 (en) 2007-04-10
AU2003232112A1 (en) 2003-12-02
NZ537139A (en) 2008-05-30
HRP20041042A2 (en) 2009-04-30
JP2005526852A (ja) 2005-09-08
AU2003232112B2 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
NO20045369L (no) Nye, substituerte sulfamatanticonvulsivaderivater
NO20051695L (no) Nye spirokondenserte kinazolinoner og deres anvendelse som fosfodiestereaseinbibitorer
NO971471L (no) Nye karboksamider med fungicid aktivitet
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
MXPA04001016A (es) Derivados de sulfonamida como inhibidores de la gamma secretasa.
BR0111596A (pt) Composto e seu uso, processo para sua produção, composição farmacêutica e processo e método para prevenir ou tratar doenças
GB2392154B (en) Protein Kinase Inhibitors
NO20066055L (no) Pyridinderivater
NO973657L (no) Trombin-inhibitorer
NO20054329L (no) Adamantanderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som innbefatter slike
WO2002064547A3 (en) Isophthalic acid derivatives as matrix metalloproteinase inhibitors
NO930517L (no) Benzimidazolylderivater, legemidler inneholdende disse, og fremgangsmaate for deres fremstilling
NO20045486L (no) Nye forbindelser og deres anvendelse
NO20052182L (no) Nye forbindelser
NO20062202L (no) Amidometylsubstituerte 2-(4-sulfonylamino)-3-hydroksy-3,4-dihydro-2H-kromen-6-yl-derivater, fremgangsmate og mellomprodukter for deres fremstilling, og legemidler som inneholder disse forbindelsene
NO20070570L (no) Forbindelser.
NO20053809L (no) Diarylmetylindenpiperidinderivater,fremgangsmate for fremstilling derav, og anvendelse derav
YU94103A (sh) Novi derivati sulfonske kiseline
NO934196L (no) N,N-disubstituerte arylcykloalkylaminer, deres salter, legemidler inneholdende disse forbindelser, deres anvendelse og fremgangsmåte for deres fremstilling
NO20061045L (no) Imidazolderivater
HUP0401080A2 (hu) Új görcsoldó sószármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ES2073258T3 (es) Nuevos derivados de la urea, su preparacion y su aplicacion en terapeutica.
AU2001255646A1 (en) Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives
DK492288A (da) Amidforbindelser, farmaceutisk praeparat indeholdende samme samt fremgangsmaade til fremstilling af forbindelserne
MXPA04005484A (es) Procedimiento de preparacion de derivados de equinocandina.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application